EE05507B1 - Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks - Google Patents

Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks

Info

Publication number
EE05507B1
EE05507B1 EEP200300239A EEP200300239A EE05507B1 EE 05507 B1 EE05507 B1 EE 05507B1 EE P200300239 A EEP200300239 A EE P200300239A EE P200300239 A EEP200300239 A EE P200300239A EE 05507 B1 EE05507 B1 EE 05507B1
Authority
EE
Estonia
Prior art keywords
percolesterolemia
heterosgococcal
rosuvastatin
family
treatment
Prior art date
Application number
EEP200300239A
Other languages
English (en)
Estonian (et)
Inventor
Ali@Raza
Howard@Gerard@Hutchinson
Original Assignee
AstraZeneca@AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05507(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca@AB filed Critical AstraZeneca@AB
Publication of EE200300239A publication Critical patent/EE200300239A/xx
Publication of EE05507B1 publication Critical patent/EE05507B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300239A 2000-11-22 2001-11-16 Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks EE05507B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (2)

Publication Number Publication Date
EE200300239A EE200300239A (et) 2003-08-15
EE05507B1 true EE05507B1 (et) 2012-02-15

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300239A EE05507B1 (et) 2000-11-22 2001-11-16 Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks

Country Status (35)

Country Link
US (1) US6858618B2 (ru)
EP (1) EP1339409B1 (ru)
JP (2) JP5062940B2 (ru)
KR (1) KR100815042B1 (ru)
CN (1) CN1268339C (ru)
AR (1) AR031766A1 (ru)
AT (1) ATE394103T1 (ru)
AU (2) AU1416502A (ru)
BG (1) BG66009B1 (ru)
BR (1) BR0115511A (ru)
CA (1) CA2429263C (ru)
CY (1) CY1110428T1 (ru)
CZ (1) CZ301583B6 (ru)
DE (1) DE60133921D1 (ru)
DK (1) DK1339409T3 (ru)
EE (1) EE05507B1 (ru)
ES (1) ES2305118T3 (ru)
GB (1) GB0028429D0 (ru)
HK (1) HK1056691A1 (ru)
HU (1) HUP0301380A3 (ru)
IL (2) IL155919A0 (ru)
IS (1) IS6819A (ru)
MX (1) MXPA03004336A (ru)
MY (1) MY134902A (ru)
NO (1) NO326245B1 (ru)
NZ (1) NZ525754A (ru)
PL (1) PL365386A1 (ru)
PT (1) PT1339409E (ru)
RU (1) RU2294744C2 (ru)
SI (1) SI1339409T1 (ru)
SK (1) SK6212003A3 (ru)
TW (1) TWI238720B (ru)
UA (1) UA75614C2 (ru)
WO (1) WO2002041895A1 (ru)
ZA (1) ZA200303636B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
KR20060022647A (ko) * 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
EP1562912A2 (en) * 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
ATE507209T1 (de) * 2003-12-02 2011-05-15 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
CN1988902A (zh) * 2004-05-26 2007-06-27 Kgk协同公司 含有类黄酮和生育三烯酚的功能性食品及其方法
CA2573857A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
ES2363160T3 (es) 2004-07-27 2011-07-22 Gilead Sciences, Inc. Conjugados de fosfonato nucelosidico como agentes anti-vih.
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
EP1851206B1 (en) * 2005-02-22 2012-08-15 Teva Pharmaceutical Industries, Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
JP2008515931A (ja) * 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 結晶形ロスバスタチン中間体
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
RU2018128393A (ru) 2012-09-17 2019-03-14 Мадригал Фармасьютикалз, Инк. Способ синтеза аналогов гормонов щитовидной железы и их полиморфов
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
WO2019027920A1 (en) 2017-08-01 2019-02-07 Gilead Sciences, Inc. CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS
CR20210669A (es) 2019-05-27 2022-05-05 Immatics Us Inc Vectores víricos y uso de los mismos en terapias celulares adoptivas
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離cd8+選擇t細胞的方法
TW202245775A (zh) * 2021-02-01 2022-12-01 美商瑪德瑞高製藥公司 用於治療肝病症或脂質病症之瑞舒伐他汀(Rosuvastatin)和瑞司美替隆(Resmetirom)的治療組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1322289B1 (en) * 2000-09-20 2007-07-25 Jagotec AG Spray drying process of compositions containing fenofibrate

Also Published As

Publication number Publication date
KR20030048479A (ko) 2003-06-19
NO20032292L (no) 2003-07-17
PT1339409E (pt) 2008-07-07
SI1339409T1 (sl) 2008-08-31
KR100815042B1 (ko) 2008-03-18
AR031766A1 (es) 2003-10-01
JP2004522714A (ja) 2004-07-29
IL155919A (en) 2009-09-01
PL365386A1 (en) 2005-01-10
AU2002214165B9 (en) 2013-07-04
NO20032292D0 (no) 2003-05-21
CZ20031406A3 (cs) 2003-09-17
DK1339409T3 (da) 2008-09-08
ATE394103T1 (de) 2008-05-15
BR0115511A (pt) 2003-12-30
CZ301583B6 (cs) 2010-04-21
BG107811A (bg) 2004-03-31
BG66009B1 (bg) 2010-10-29
CA2429263C (en) 2009-03-17
ZA200303636B (en) 2004-08-12
JP5062940B2 (ja) 2012-10-31
US6858618B2 (en) 2005-02-22
TWI238720B (en) 2005-09-01
CN1268339C (zh) 2006-08-09
IS6819A (is) 2003-05-19
HUP0301380A2 (hu) 2003-10-28
GB0028429D0 (en) 2001-01-10
NZ525754A (en) 2004-10-29
RU2294744C2 (ru) 2007-03-10
ES2305118T3 (es) 2008-11-01
HK1056691A1 (en) 2004-02-27
CA2429263A1 (en) 2002-05-30
CY1110428T1 (el) 2015-04-29
DE60133921D1 (de) 2008-06-19
JP2010031047A (ja) 2010-02-12
US20040072852A1 (en) 2004-04-15
SK6212003A3 (en) 2003-11-04
WO2002041895A1 (en) 2002-05-30
MY134902A (en) 2007-12-31
UA75614C2 (ru) 2006-05-15
IL155919A0 (en) 2003-12-23
AU2002214165B2 (en) 2006-12-14
MXPA03004336A (es) 2003-08-19
CN1630520A (zh) 2005-06-22
NO326245B1 (no) 2008-10-27
EP1339409B1 (en) 2008-05-07
EE200300239A (et) 2003-08-15
AU1416502A (en) 2002-06-03
EP1339409A1 (en) 2003-09-03
HUP0301380A3 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
ID30590A (id) Celana sekali pakai jenis-celana pendek
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
DK1604680T3 (da) Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
EE200300485A (et) Tiohüdantoinid ja nende kasutamine diabeedi raviks
DE50112013D1 (de) Deodorantien und antiperspirantien
NO20024099D0 (no) Lavdose entecavir-formulering og anvendelse
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
NO20034159D0 (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
IS6918A (is) Meðferð erfiðra æxla með notkun epóþílon afleiða
AR027945A1 (es) Uso de pramipexol en el tratamiento de transtornos de adiccion
NO20032122L (no) Forbedret behandling
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE60223576D1 (de) Hautbehandlungszusammensetzung
NO20041968L (no) Anvendelse av cystationin
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
ID30381A (id) Penggunaan arilalkanoilpiridazina

Legal Events

Date Code Title Description
HD1A Correction of address
MM4A Lapsed by not paying the annual fees

Effective date: 20161116